Home › Diffuse Large B-Cell Lymphoma › Montana
Pag-aaral pangklinika para sa Diffuse Large B-Cell Lymphoma sa Montana
4 pag-aaral para sa Diffuse Large B-Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa Montana.
Mga Lungsod sa Montana
Opisyal na teksto ng pag-aaral (English)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Billings Clinic Cancer Center, Billings
- Community Medical Center, Missoula
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06649812A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- St. Vincent Frontier Cancer Center-Research ( Site 0108), Billings
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05139017A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Bozeman Health Deaconess Hospital ( Site 0183), Bozeman
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06890884A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0178), Billings
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06717347Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.